Annual report pursuant to Section 13 and 15(d)

CONSOLIDATED BALANCE SHEETS

v3.10.0.1
CONSOLIDATED BALANCE SHEETS - USD ($)
Dec. 31, 2018
Dec. 31, 2017
Current assets    
Cash and cash equivalents $ 68,379,000 $ 84,043,000
Marketable securities - available-for-sale debt securities 136,755,000 124,218,000
Accounts receivable, net of allowance for doubtful accounts of $0 and $0 192,000 206,000
Other current assets and prepaid expenses (including current portion of clinical materials) 25,769,000 21,716,000
Total current assets 231,095,000 230,183,000
Restricted cash 4,097,000 4,253,000
Clinical materials 3,953,000 4,695,000
Property, plant and equipment, net 36,118,000 40,679,000
Intangibles, net 1,473,000 1,337,000
Deferred revenue   38,735,000
Total assets 276,736,000 281,147,000
Current liabilities    
Accounts payable 4,083,000 8,378,000
Accrued expenses and other accrued liabilities 20,354,000 27,201,000
Total current liabilities 24,437,000 74,314,000
Other liabilities, non-current 5,414,000 3,849,000
Total liabilities 29,851,000 78,163,000
Contingencies and commitments - Note 9
Stockholders' equity    
Common stock - Ordinary shares par value ?0.001, 701,103,126 authorized and 627,454,270 issued and outstanding (2017: 701,103,126 authorized and 562,119,334 issued and outstanding) 939,000 854,000
Additional paid in capital 574,208,000 455,401,000
Accumulated other comprehensive loss (9,763,000) (21,641,000)
Accumulated deficit (318,499,000) (231,630,000)
Total stockholders' equity 246,885,000 202,984,000
Total liabilities and stockholders' equity $ 276,736,000 $ 281,147,000